U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX4145829: GSM3167462: eMSCs_T1_S9; Homo sapiens; RNA-Seq
1 ILLUMINA (Illumina HiSeq 3000) run: 67.1M spots, 3.4G bases, 1.2Gb downloads

Submitted by: NCBI (GEO)
Study: The transcriptome of human endometrial mesenchymal stem cells under TGFßR inhibition reveals improved potential for cell-based therapies
show Abstracthide Abstract
Mesenchymal stem/stromal cells (MSCs) are multipotent cells with favorable properties for cell therapy and regenerative medicine. Human endometrium harbors a small population of perivascular, clonogenic MSCs (eMSCs) identified by the SUSD2 marker. As for other MSCs, eMSCs require extensive in vitro expansion to generate clinically relevant numbers of cells, resulting in spontaneous differentiation, replicative senescence, and cell death, decreasing therapeutic potency. We previously demonstrated that A83-01, a TGF-b receptor inhibitor maintained eMSCs clonogenicity, promoted proliferation, prevented apoptosis and maintained MSC function in vitro. Here we compare the transcriptome of passaged eMSCs from six women cultured with and without A83-01 for 7 days. We identified 1206 differentially expressed genes using a false discovery rate cut-off at 0.01 and fold change >2. Significant enrichment of genes involved in inflammatory responses, angiogenesis, cell migration and proliferation, and reduced smooth muscle proliferation, collagen fibril and extracellular matrix organization genes were revealed. TGF-b, Wnt and Akt signaling pathways were decreased. Anti-fibrotic and anti-apoptotic genes were induced, and fibroblast proliferation and myofibroblast related genes were down-regulated. We validated the enhanced potency of A83-01-treated eMSCs and found increased MSC potency genes (TWIST1, TWIST2, JAG1, LIFR, and SLIT2) and no pluripotency gene expression. Increased angiogenic capacity was functionally demonstrated in vitro, and our angiogenic and cytokine protein arrays further confirmed the angiogenic, antifibrotic and immunomodulatory phenotype of A83-01-treated eMSCs. Overall, we showed that eMSCs culture expanded with A83-01 have improved potential for cell-therapies and regenerative medicine applications. Overall design: This data is RNA-seq of passaged 6 endometrial mesenchymal stem cells treated with DMSO control or 1mM A83-01. Each group has cells from six independent female donors (paired untreated/U and A83-01 treated/T1).
Sample: eMSCs_T1_S9
SAMN09288338 • SRS3359449 • All experiments • All runs
Organism: Homo sapiens
Library:
Instrument: Illumina HiSeq 3000
Strategy: RNA-Seq
Source: TRANSCRIPTOMIC
Selection: cDNA
Layout: SINGLE
Construction protocol: RNA was extracted using PureLink® RNA mini Kit (Ambion, Invitrogen) including treatment with RNase-free DNase (QIAGEN). Sequencing libraries prepared from 1mg input RNA (depleted of ribosomal RNA) with Illumina TruSeq Poly-A mRNA Library Pro Kit protocol 15031047 RevD (Illumina, Hayward, CA)
Experiment attributes:
GEO Accession: GSM3167462
Links:
Runs: 1 run, 67.1M spots, 3.4G bases, 1.2Gb
Run# of Spots# of BasesSizePublished
SRR723999867,088,0643.4G1.2Gb2018-12-21

ID:
5632097

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...